SIGNATOPE offers next generation quantitative assays for your protein biomarker of interest!
SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE´s immunoassays. The short epitope allows us to establish quantitative assays for the same protein in different species and for isoforms of protein families. Even immunoassays for notoriously difficult proteins like drug transporters can be established while providing the speed and the sensitivity of an antibody-based method.
Deleted:
Our Services
Conferences
-
-
We’re pleased to announce Signatope’s participation in the 2nd ISSX 2-Day Workshop on Quantitative LC-MS/MS Proteomics, scheduled for June 27-28, 2024, at the Certara UK Offices in Sheffield, UK. Our CEO, Oliver Pötz, alongside Senior Scientist Helen Hammer, will present on the first day of the …
Read more
-
We are pleased to announce that Signatope will be exhibiting at the Society of Toxicology (SOT) Conference 2024 in Salt Lake City, Utah, from March 10th to March 14th. Join us at booth number 710, where we will be showcasing our latest advancements in toxicology research. …
Read more
-
Reutlingen, 14.11.2022 — SIGNATOPE ist in der vergangenen Woche mit dem Deloitte Technology Fast 50 Award ausgezeichnet worden. Mit dem Award prämiert die Beratungs- und Prüfungsgesellschaft Deloitte jedes Jahr die 50 am schnellsten wachsenden Unternehmen der Tech-Branche, basierend auf ihrem prozentualen Umsatzwachstum der vergangenen vier Geschäftsjahre. …
Read more
-
Oliver an Hannes went to the TransBioLine Consortium Meeting 2022! The project provides a unique opportunity to access a large expert and knowledge network, including data and samples from clinical trials, to enable the global safety qualification of identified novel biomarkers. The TransBioLine project aims to …
Read more
Contact Us
Social Media
